Comparison of 100cc prostates undergoing aquablation for benign prostatic hyperplasia

摘要

IntroductionSurgical options for benign prostatic hyperplasia (BPH) become limited when treating large prostates due to steep learning curves and less effective treatment. Aquablation (AquaBeam System, PROCEPT BioRobotics, Inc., USA) could remedy this. We compare the effectiveness of Aquablation in large prostates between 80cc and 100cc and very large prostates >100cc.MethodsWATER II (NCT03123250) is a prospective, multicenter, international clinical trial of Aquablation for the surgical treatment of LUTS/BPH in men of age 45-80years with prostates between 80cc and 150cc. Aquablation was performed using the AquaBeam System. The reported analysis compares the subgroup of patients with a baseline prostate size of 100cc. Students' t test was used for continuous variables and Fisher's test for ordinal/binary variables.ResultsOf 114 screened patients, 101 meeting eligibility criteria were enrolled at 13 US and 3 Canadian sites between September and December 2017. Mean operative time was 31.28min in the 100cc subgroup. The average length of stay following the procedure for the 100cc subgroup. Mean changes in International Prostate Symptom Score (IPSS), IPSS quality of life, and IPSS voiding and storage subscores were substantial, occurring soon after treatment and averaging (at 3months) 16.5, 2.8, 10.6, and 5.8 points, respectively (all p 100cc prostate cohorts. It is safe and effective in patients with large prostate glands (>100cc) with a smoother learning curve.